Akorn has launched its generic form of loteprednol etabonate ophthalmic suspension 0.5%, according to a company press release.
The FDA approved the drug in its generic form in April.
Loteprednol etabonate ophthalmic suspension 0.5% is indicated for the treatment of postoperative inflammation after ocular surgery, as well as for steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segments of the eye.
“This launch underscores our ability to execute on development and manufacturing of complex ophthalmic suspensions. With the launch of this
Uncategorized